Page 1

EX - 99.1 2 nbix - 20210630exhibit991.htm EX - 99.1 Neurocrine Biosciences Reports Second Quarter 2021 Financial Results INGREZZAⓇ ( valbenazine ) Second Quarter 2021 Net Product Sales of $ 265 Million with Approximately 48,900 Total Prescriptions Phase 3 Registrational Program of Valbenazine for the Treatment of Chorea Associated with Huntington Disease Fully Enrolled with Top - Line Data Expected by Year - End SAN DIEGO , August 3 , 2021 - Neurocrine Biosciences , Inc. ( Nasdaq : NBIX ) today announced its financial results for the second quarter ended June 30 , 2021 . " We helped more tardive dyskinesia patients than ever before as our second quarter results reflect sustained growth for INGREZZA . While 8 out of 10 patients still remain undiagnosed , the underlying opportunity to improve the lives of patients with TD remains strong . Therefore , we continue to invest in healthcare provider and patient - focused awareness campaigns to help improve TD diagnosis and treatment rates , " said Kevin Gorman , Ph.D. , Chief Executive Officer of Neurocrine Biosciences . " We remain committed to advancing our R & D pipeline and are making steady progress towards initiating 9 mid - to - late - stage clinical trials this year . With significant long - term commercial growth opportunities and a diverse and growing pipeline , we are well positioned to become a leading neuroscience - focused biopharmaceutical company . " Financial Highlights ( unaudited , in millions , except per share data ) Revenues : Product sales , net Collaboration revenue Total revenues GAAP Research and Development ( R & D ) Non - GAAP R & D GAAP Selling , General and Administrative ( SG & A ) Non - GAAP SG & A GAAP net income GAAP net income per share – diluted Non - GAAP net income Non - GAAP net income per share – diluted $ $ $ LA LA $ $ A LA $ $ LA LA $ $ LA LA $ ( unaudited , in millions ) Total cash , cash equivalents and debt securities available - for - sale Three Months Ended June 30 , 2021 266.8 $ 22.1 288.9 $ 74.8 $ 65.6 $ 143.2 $ 123.8 $ 42.3 $ 0.43 $ 61.3 $ 0.63 LA LA $ 2020 267.6 $ 34.8 302.4 $ 80.9 $ 51.0 $ 96.5 76.9 LA LA $ LA LA $ 79.6 $ 0.81 $ 139.1 $ 1.42 LA LA $ $ Six Months Ended June 30 , 2021 497.8 $ 27.7 525.5 $ 148.0 $ 123.8 $ 272.2 $ 234.9 $ Exhibit 99.1 74.4 $ 0.76 $ 109.2 1.11 June 30 , 2021 $ $ 1,222.7 $ 2020 498.7 40.8 539.5 139.2 101.6 214.3 179.6 117.0 1.20 218.2 2.24 December 31 , 2020 1,028.1